3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

Abstract presented at ESMO 2020 (Virtual conference)

J. Bourhis¹,  XS. Sun², C. Le Tourneau⁵, Y. Pointreau³, C. Sire⁴, MC. Kaminsky-Forret⁷, A. Coutte⁶, M. Alfonsi⁸, P. Boisselier⁹, L. Martin¹⁰, JP. Delord¹¹, F. Clatot¹², J. Biau¹³,
F. Rolland¹⁴, K. Gollmer¹⁵, S. Szyldergemajn¹⁵, C. Even¹⁶ and Y. Tao¹⁶.

1. CHUV, Lausanne, Switzerland
2. Hôpital Nord Franche-Comté, Montbéliard, France
3. Centre Jean Bernard, Le Mans, France
4. Centre Hospitalier de Bretagne Sud – Hôpital du Scorff, Lorient, France
5. Institut Curie, Paris, France
6. C.H.U. Sud Amiens, Amiens, France
7. L’Institut de Cancérologie de Lorraine (ICL) Alexis Vautrin, Vandoeuvre-lès-Nancy, France
8. Institut Sainte Catherine, Avignon, France
9. ICM – Val d’Aurelle, Montpellier, France
10. Centre Guillaume le Conquérant, Le Havre, France
11. Institut Claudius Regaud – Oncopole, Toulouse, France
12. Centre Henri Becquerel, Rouen, France
13. Centre Jean Perrin, Clermont-Ferrand, France
14. Institut de Cancérologie de l’Ouest (ICO) René Gauducheau, Saint-Herblain, France
15. Debiopharm International SA, Lausanne, Switzerland
16. Institute Gustave Roussy, Villejuif, France